For the quarter ended September 2025, NovoCure (NVCR) reported revenue of $167.2 million, up 7.8% over the same period last year. EPS came in at -$0.33, compared to -$0.28 in the year-ago quarter.
The reported revenue represents a surprise of +5.76% over the Zacks Consensus Estimate of $158.1 million. With the consensus EPS estimate being -$0.42, the EPS surprise was +21.43%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how NovoCure performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Geographic Revenues- Greater China: $5.6 million versus $3.65 million estimated by two analysts on average.
- Geographic Revenues- Japan: $9.39 million compared to the $9.12 million average estimate based on two analysts.
- Geographic Revenues- United States: $96.61 million versus $95.13 million estimated by two analysts on average.
View all Key Company Metrics for NovoCure here>>>
Shares of NovoCure have returned -3.6% over the past month versus the Zacks S&P 500 composite's +3.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
NovoCure Limited (NVCR): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
